Dasher Neuroscience schließt die Patientenrekrutierung für die weltweite klinische Phase-2-Studie mit dem führenden KI-basierten Wirkstoffkandidaten YA-101 gegen Multisystematrophie (MSA) ab

Phase 2YA-101Positive

AI Analysis

Summary

Dasher Neuroscience completed patient recruitment for its global Phase 2 clinical trial of YA-101, an AI-based drug candidate for multisystematic atrophy (MSA), a rare neurological disorder.

Clinical Trial Data

Phase

Phase 2

Outcome Details

Patient recruitment completed for global Phase 2 clinical trial

Importance:6/10

Sentiment:

0.60

Phase 2Clinical TrialPatient RecruitmentCNSAI-driven drug discoveryRare Disease

Related Companies

$7829

Read the original article

Published by PR Newswire Biotech on July 30, 2026 5:29 AM

Read Original